default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

Last trial OKed for Eylea to prevent blindness in premature infants

Lee Hye-seon  Published 2019.08.13  12:42  Updated 2019.08.13 12:42

공유
default_news_ad2

The Korean drug regulator has approved a phase-3 clinical trial on Eylea (ingredient: aflibercept), an anti-vascular endothelial growth factor (anti-VEGF) injection, for the treatment of retinopathy of prematurity (ROP) in premature babies.

Bayer’s macular degeneration treatment Eylea

The Ministry of Food and Drug Safety on Monday granted Bayer Korea to go ahead with the phase-3 study on Eylea.

The study will evaluate the long-time result of 100 participants, including three Koreans who receive ROP treatment. Samsung Medical Center, Asan Medical Center, and Soonchunhyang University Cheonan Hospital will participate in the study.

Eylea is an anti-VEGF injection, treating macular degeneration. Globally, Bayer has been conducting the phase-3 study since June to confirm whether Eylea will prevent blindness in premature infants with ROP.

ROP occurs in premature infants who have incomplete development of blood vessels for the retina. It is one of the major causes of blindness in children.

In Korea, Eylea is indicated for neovascular wet age-related macular degeneration as well as visual impairments caused by retinal vein occlusion, diabetic macular edema, and choroidal neovascularization due to pathological myopia.

lhs@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch